A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Twenty‐five patients with hand tremor of 2 + (moderate) to 4 + (severe) on the tremor severity rating scale were randomized to receive either 50 U of botulinum toxin (BTX) type A (Allergan, Irvine, CA) or placebo injections into the wrist flexors and extensors of the dominant limb. If patients failed to respond to the initial injection, they were eligible to receive another injection of 100 U 4 weeks later. Rest, postural, and kinetic tremors were evaluated at 2‐ to 4‐week intervals over a 16‐week study period using tremor severity rating scales, accelerometry, and assessments of improvement and disability. A signigicant improvment (p < 0.05) was observed on the tremor severity rating scale 4 weeks after injection in patients treated with BTX as compared with placebo, and this effect was maintained for the duration of the study. Four weeks after injection, 75% of BTX‐treated patients vs. 27% of placebo‐treated patients (p < 0.05). reported mild to moderate improvement (peak effect rating ≥2). There were no significant improvements in functional rating scales, although trends were observed for some items. Postural accelerometry measurements showed a ≥30% reduction in amplitude in nine of 12 BTX‐treated subjects and in one of nine placebo‐treated subjects (p < 0. 05). Although all patients treated with BTX reported some degree of finger weakness, no severe, irreversible, or unexpected adverse events occurred. Chemodenervation with BTX may significantly ameliorate essential hand tremor in patients who fail to improve with conventional pharmacologic therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This approach has been used successfully with the advantage of providing very targeted relief (46–51).”
From Could Wearable and Mobile Technology Improve the Management of Essential Tremor? (2018) · cites this paper as [47]
Citations
Cites
The Sickness Impact Profile: Development and Final Revision of a Health Status Measure
Bergner, M., Bobbitt, R. A., Carter, W. B., & Gilson, B. S. (1981) · Medical Care · doi:10.1097/00005650-198108000-00001 · Cited by 4,619
Therapeutic Uses of Botulinum Toxin
Oates, J. A., Wood, A. J. J., Jankovic, J., & Brin, M. F. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104253241707 · Cited by 801
Self-citationParkinson's Disease and Movement Disorders
Kieburtz, K. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540220013003 · Cited by 616
Landis, J. R., Heyman, E. R., & Koch, G. G. (1978) · International Statistical Review / Revue Internationale de Statistique · doi:10.2307/1402373 · Cited by 454
A study of hereditary essential tremor
Bain, P. G., Findley, L. J., Thompson, P. D., Gresty, M. A., Rothwell, J. C., Harding, A. E., & Marsden, C. D. (1994) · Brain · doi:10.1093/brain/117.4.805 · Cited by 392
Tonic vibration reflex and muscle afferent block in writer's cramp
Kaji, R., Rothwell, J. C., Katayama, M., Ikeda, T., Kubori, T., Kohara, N., Mezaki, T., Shibasaki, H., & Kimura, J. (1995) · Annals of Neurology · doi:10.1002/ana.410380206 · Cited by 300
Is dystonia a sensory disorder?
Hallett, M. (1995) · Annals of Neurology · doi:10.1002/ana.410380203 · Cited by 297
Rivner, M. H. (1995) · Neurology · doi:10.1212/wnl.45.6.1244-a · Cited by 280
Anatomic guide for the electromyographer--the limbs
Delagi, E. F., & Perotto, A. (1980) · Thomas eBooks · Cited by 260
Lees, A. (1995) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.59.3.345-d · Cited by 255
Research works printed but not linked: 2
- Lou JS, 1991, Current neurology, 199
- Ludlow CL, 1989, Treatment of voice tremor with botulinum toxin injection [Abstract], Neurology, 39, 353
Cited by
Simpson, D. M., Blitzer, A., Brashear, A., Comella, C., Dubinsky, R., Hallett, M., Jankovic, J., Karp, B., Ludlow, C. L., Miyasaki, J. M., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000311389.26145.95 · Cited by 618
Self-citationTreatment of patients with essential tremor
Deuschl, G., Raethjen, J., Hellriegel, H., & Elble, R. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70322-7 · Cited by 428
Botulinum toxin in clinical practice
Jankovic, J. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.034702 · Cited by 408
Self-citationLong-term Evaluation of Bilateral Fetal Nigral Transplantation in Parkinson Disease
Hauser, R. A., Freeman, T. B., Snow, B. J., Nauert, M., Gauger, L., Kordower, J. H., & Olanow, C. W. (1999) · Archives of Neurology · doi:10.1001/archneur.56.2.179 · Cited by 353
Louis, E. D. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)00991-9 · Cited by 334
Jankovic, J. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70574-9 · Cited by 332
Self-citationSafety of botulinum toxin type A: a systematic review and meta-analysis
Naumann, M. K., & Jankovic, J. J. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125003962 · Cited by 327
Self-citationEvidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders
Hallett, M., Albanese, A., Dressler, D., Segal, K. R., Simpson, D. M., Truong, D., & Jankovic, J. (2013) · Toxicon · doi:10.1016/j.toxicon.2012.12.004 · Cited by 272
Self-citationLouis, E. D. (2001) · New England Journal of Medicine · doi:10.1056/nejmcp010928 · Cited by 258
Treatment of hyperkinetic movement disorders
Jankovic, J. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70183-8 · Cited by 252
Self-citationA randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor
Brin, M. F., Lyons, K. E., Doucette, J., Adler, C. H., Caviness, J. N., Comella, C. L., Dubinsky, R. M., Friedman, J. H., Manyam, B. V., Matsumoto, J. Y., et al. (2001) · Neurology · doi:10.1212/wnl.56.11.1523 · Cited by 233
“Examiner and patient subjective assessment of response compared with the last visit were scored on a scale ranging from severe worsening (24) to complete abolishment of symptoms (14).”
BackgroundMDS evidence‐based review of treatments for essential tremor
Ferreira, J. J., Mestre, T. A., Lyons, K. E., Benito‐León, J., Tan, E., Abbruzzese, G., Hallett, M., Haubenberger, D., Elble, R., Deuschl, G., et al. (2019) · Movement Disorders · doi:10.1002/mds.27700 · Cited by 215
Essential tremor: diagnosis and management
Shanker, V. (2019) · BMJ · doi:10.1136/bmj.l4485 · Cited by 182
Botulinum Toxin in Movement Disorders: An Update
Anandan, C., & Jankovic, J. J. (2021) · Toxins · doi:10.3390/toxins13010042 · Cited by 171
“, 1996 [212] Randomized double-blind placebo-controlled trial Assesses BoNTA for essential hand tremor n = 25 BoNTA or Placebo injected into wrist flexors and extensors Tremors improved at 4 weeks (p < 0.”
BackgroundSelf-citationTreatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems
Hagerman, R. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s1794 · Cited by 131
“Placebo controlled trials of BTX in essential tremor have shown that in some cases there is signifi cant reduction of tremor amplitude, but only mild functional improvement associated with problematic limb weakness (Jankovic et al 1996; Brin et al 2001; Cordivari et al 2004).”
Gabapentin for essential tremor: A multiple-dose, double-blind, placebo-controlled trial
Ondo, W., Hunter, C., Vuong, K. D., Schwartz, K., & Jankovic, J. (2000) · Movement Disorders · doi:10.1002/1531-8257(200007)15:4<678::aid-mds1012>3.0.co;2-0 · Cited by 135
Self-citationIs it feasible to reconstruct body segment 3-D position and orientation using accelerometric data?
Giansanti, D., Macellari, V., Maccioni, G., & Cappozzo, A. (2003) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2003.809490 · Cited by 127
“In the literature, ACs were used to monitor the level of human physical activity [8], to assess tremors [7] or to measure the deformation wave that travels along the skeletal system when the foot impacts the floor during locomotion [9].”
MethodEssential tremor quantification during activities of daily living
Heldman, D. A., Jankovic, J., Vaillancourt, D. E., Prodoehl, J., Elble, R. J., & Giuffrida, J. P. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.04.017 · Cited by 110
“Previously, accelerometers (actigraphy), gyroscopes, and electromyography (EMG) have been used extensively to obtain quantitative measurements of tremor in both Parkinson’s disease (PD) and ET [7,11–14].”
MethodSelf-citationTruong, D. D., & Jost, W. H. (2006) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2006.06.002 · Cited by 122
“Both open-label and controlled studies in patients with essential tremor have shown improvement with BoNT [121–125].”
BackgroundBasic immunological aspects of botulinum toxin therapy
Atassi, M. Z. (2004) · Movement Disorders · doi:10.1002/mds.20020 · Cited by 111
Kaufmann, H., Schurch, B., Silberstein, S., Simpson, D. M., Naumann, M., So, Y. T., Argoff, C. E., Childers, M. K., Dykstra, D. D., & Gronseth, G. (2008) · Cited by 110
Essential tremor: differential diagnosis and current therapy
Pahwa, R., & Lyons, K. E. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00259-6 · Cited by 112
Botulinum Toxin Type A for Treating Voice Tremor
Adler, C. H., Bansberg, S. F., Hentz, J. G., Ramig, L. O., Buder, E. H., Witt, K., Edwards, B. W., Krein-Jones, K., & Caviness, J. N. (2004) · Archives of Neurology · doi:10.1001/archneur.61.9.1416 · Cited by 103
Benefits and Risks of Pharmacological Treatments for Essential Tremor
Lyons, K. E., Pahwa, R., Comella, C. L., Eisa, M. S., Elble, R. J., Fahn, S., Jankovic, J., Juncos, J. L., Koller, W. C., Ondo, W. G., et al. (2003) · Drug Safety · doi:10.2165/00002018-200326070-00003 · Cited by 103
Self-citationEssential tremor—the most common movement disorder in older people
Thanvi, B., Lo, N., & Robinson, T. (2006) · Age and Ageing · doi:10.1093/ageing/afj072 · Cited by 102
The current use of botulinum toxin
Mahant, N., Clouston, P. D., & Lorentz, I. T. (2000) · Journal of Clinical Neuroscience · doi:10.1054/jocn.2000.0684 · Cited by 100
An update on new and unique uses of botulinum toxin in movement disorders
Jankovic, J. J. (2017) · Toxicon · doi:10.1016/j.toxicon.2017.09.003 · Cited by 97
“Two double-blind, placebo-controlled trials demonstrated clinically meaningful improvements in tremor but in both studies the reduction in amplitude was accompanied by weakness, especially involving finger extensors (Jankovic et al., 1996; Brin et al., 2001).”
BackgroundSelf-citationZappia, M., Albanese, A., Bruno, E., Colosimo, C., Filippini, G., Martinelli, P., Nicoletti, A. S. Q., Quattrocchi, G., Abbruzzese, G., Berardelli, A., et al. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6628-x · Cited by 100
“In the RCTs [94, 95], weakness of the injected muscles was a common AE of BTXA, but not of the placebo.”
BackgroundMethodInfluentialParkinson's disease in women: Mechanisms underlying sex differences
Vaidya, B., Dhamija, K., Guru, P., & Sharma, S. S. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173862 · Cited by 99
Hopfner, F., & Deuschl, G. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00899-2 · Cited by 100
Mostile, G., Giuffrida, J. P., Adam, O. R., Davidson, A., & Jankovic, J. (2010) · Movement Disorders · doi:10.1002/mds.23201 · Cited by 86
Self-citationDisease-oriented approach to botulinum toxin use
Jankovic, J. J. (2008) · Toxicon · doi:10.1016/j.toxicon.2008.11.013 · Cited by 93
“Two double-blind, placebo-controlled studies demonstrated that BoNT was safe and effective in the treatment of essential tremor (Jankovic et al., 1996; Brin et al., 2001).”
BackgroundSelf-citationTransducer‐based evaluation of tremor
Haubenberger, D., Abbruzzese, G., Bain, P. G., Bajaj, N., Benito‐León, J., Bhatia, K. P., Deuschl, G., Forjaz, M. J., Hallett, M., Louis, E. D., et al. (2016) · Movement Disorders · doi:10.1002/mds.26671 · Cited by 87
Schneider, S. A., & Deuschl, G. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0230-5 · Cited by 96
“This includes one RCT parallel group study [75] using a 2-staged injection pattern with low-dose injections into hand flexors and extensors followed by a higher dose 4 weeks later if patients were unresponsive to the initial dose.”
MethodCarbenoxolone and mefloquine suppress tremor in the harmaline mouse model of essential tremor
Martin, F. C., & Handforth, A. (2006) · Movement Disorders · doi:10.1002/mds.20940 · Cited by 79
A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremor
van der Walt, A., Sung, S., Spelman, T., Marriott, M. P., Kolbe, S., Mitchell, P. J., Evans, A. H., & Butzkueven, H. (2012) · Neurology · doi:10.1212/wnl.0b013e31825dcdd9 · Cited by 83
Samotus, O., Lee, J., & Jog, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178670 · Cited by 72
“In comparison, early tremor studies by Jankovic et al. (1996), 42–50% of patients reported mild hand weakness and 42% had moderate hand weakness with no functional hand improvement [12].”
ResultBotulinum Toxin in Parkinson Disease Tremor
Mittal, S. O., Machado, D., Richardson, D., Dubey, D., & Jabbari, B. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.06.010 · Cited by 72
Botulinum toxin and spasticity
Davis, E. C., & Barnes, M. P. (2000) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.69.2.143 · Cited by 70
Essential Tremor: Epidemiology, Diagnosis, and Treatment
Sullivan, K. L., Hauser, R. A., & Zesiewicz, T. (2004) · The Neurologist · doi:10.1097/01.nrl.0000138736.07840.b2 · Cited by 79
History of Botulinum Toxin Treatment in Movement Disorders
Jabbari, B. (2016) · Tremor and Other Hyperkinetic Movements · doi:10.5334/tohm.321 · Cited by 73
Pharmacologic Treatment of Tremor
Wasielewski, P. G., Burns, J. M., & Koller, W. C. (2008) · Movement Disorders · doi:10.1002/mds.870131316 · Cited by 63
Unlabeled uses of botulinum toxins: A review, part 1
Cheng, C. M., Chen, J., & Patel, R. P. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050137 · Cited by 62
Needle EMG guidance is rarely required
Jankovic, J. J. (2001) · Muscle & Nerve · doi:10.1002/mus.1186 · Cited by 62
Self-citationASSESSMENT: BOTULINUM NEUROTOXIN FOR THE TREATMENT OF SPASTICITY (AN EVIDENCE-BASED REVIEW)
Dobkin, B. H., Landau, W. M., Sahrmann, S., Thach, W. T., Simpson, D. M., Gracies, J.-M., Graham, K., Hallett, M., Miyasaki, J., Naumann, M., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181af0b6e · Cited by 62
Sheffield, J. K., & Jankovic, J. J. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.6.637 · Cited by 60
Self-citationMittal, S. O., Machado, D., Richardson, D., Dubey, D., & Jabbari, B. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.06.019 · Cited by 60
Treatment of essential tremor: current status
Sharma, S., & Pandey, S. (2019) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-136647 · Cited by 66
Modugno, N., Priori, A., Berardelli, A., Vacca, L., Mercuri, B., & Manfredi, M. (1998) · Muscle & Nerve · doi:10.1002/(sici)1097-4598(199812)21:12<1701::aid-mus12>3.0.co;2-k · Cited by 67
Campbell, A. M., Glover, J. G., Chiang, V., Gerrard, J. L., & Yu, J. B. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.01.013 · Cited by 60
“The Unified Tremor Rating Scale [22], which assesses activities of daily living, amplitude-based tremor observations, water pouring, and spirograph drawing.”
MethodClinical value of botulinum toxin in neurological indications
Ward, A. B., Molenaers, G., Colosimo, C., & Berardelli, A. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01650.x · Cited by 58
“It has been shown [37,38] that BONT-A can reduce tremor intensity in severe cases.”
BackgroundBotulinum toxin for the treatment of tremor
Mittal, S. O., Lenka, A., & Jankovic, J. J. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.01.023 · Cited by 60
Self-citationBotulinum Toxin for the Treatment of Hand Tremor
Niemann, N., & Jankovic, J. J. (2018) · Toxins · doi:10.3390/toxins10070299 · Cited by 57
“This is consistent with data from the first two double-blind, placebo-controlled trials of BoNT in the treatment of ET [27,28].”
ResultSelf-citationRahimi, F., Samotus, O., Lee, J., & Jog, M. (2015) · Tremor and Other Hyperkinetic Movements · doi:10.5334/tohm.240 · Cited by 55
Current Clinical Applications of Botulinum Toxin
Truong, D. D., Stenner, A., & Reichel, G. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209789271843 · Cited by 55
Diagnosis and Management of Tremor
Habib-ur-Rehman, N. A. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.16.2438 · Cited by 52
“In a randomized clinical trial of 25 patients with essential tremor of the hand, significant improvement in tremor severity rating scales was reported.(59) It was concluded that botulinum toxin has modest tremorlytic effect.”
BackgroundNew therapeutic indications for botulinum toxins
Cordivari, C., Misra, V. P., Catania, S., & Lees, A. J. (2004) · Movement Disorders · doi:10.1002/mds.20071 · Cited by 52
Handforth, A., & Martin, F. C. (2004) · Movement Disorders · doi:10.1002/mds.20147 · Cited by 50
Zonisamide for essential tremor: An evaluator‐blinded study
Handforth, A., Martin, F. C., Kang, G. A., & Vanek, Z. F. (2009) · Movement Disorders · doi:10.1002/mds.22418 · Cited by 49
“Four subjects did not exceed 200 mg/day; of 21 who did, 15 reported 22 adverse effects, including drowsiness (6), poor energy (5), imbalance (3), altered taste (2), longer sleep, rhinitis, psychomotor retardation, diarrhea, abdominal discomfort, and nausea (1 each).”
BackgroundEssential Tremor: Diagnosis and Treatment
Chen, J. J., & Swope, D. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.10.1105.32750 · Cited by 52
“flexors and extensors and followed for 16 weeks.(60) Based on accelerometric data and ratings of tremor severity scales, 75% of BTXA–treated patients experienced mild-to-moderate improvement 4 weeks after treatment compared with 27% of placebo-treated patients (p<0.”
ResultBotulinum toxin treatment for functional disability induced by essential tremor
Pacchetti, C., Mancini, F., Bulgheroni, M., Zangaglia, R., Cristina, S., Sandrini, G., & Nappi, G. (2000) · Neurological Sciences · doi:10.1007/s100720070049 · Cited by 48
“The use of botulinum toxin type A (BTX) for the treatment of hand tremor has now been established [1-5].”
BackgroundMethodInfluentialBotulinum Toxin Treatment of Movement Disorders
Safarpour, Y., & Jabbari, B. (2018) · Current Treatment Options in Neurology · doi:10.1007/s11940-018-0488-3 · Cited by 51
Samotus, O., Rahimi, F., Lee, J., & Jog, M. (2016) · PLOS ONE · doi:10.1371/journal.pone.0153739 · Cited by 46
“Selection of tremulous muscles has previously been established by using a fixed method, injecting only flexor and extensor wrist muscles [10,18,19], by using single joint surface EMG electrodes [8], or by combining accelerometry and surface EMG [11].”
MethodBotulinum Toxin for the Treatment of Movement Disorders
Thenganatt, M. A., & Fahn, S. (2012) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-012-0286-3 · Cited by 52
“Transient finger weakness was present in all patients, although not disabling [88].”
BackgroundInfluentialFluid and Biopsy Based Biomarkers in Parkinson's Disease
Coughlin, D. G., & Irwin, D. J. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01379-z · Cited by 48
Scales for hyperkinetic disorders: A systematic review
Pietracupa, S., Bruno, E., Cavanna, A. E., Falla, M., Zappia, M., & Colosimo, C. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.08.1544 · Cited by 49
Review on clinical update of essential tremor
Chunling, W., & Zheng, X. (2016) · Neurological Sciences · doi:10.1007/s10072-015-2380-1 · Cited by 45
“Other pharmacotherapies: (1) botulinum toxin type A (BTXA): 50U BTXA is effective in ET patients with arm tremors [58].”
BackgroundReview: Diagnosis and management of essential tremor and dystonic tremor
Gironell, A., & Kulisevsky, J. (2009) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285609104791 · Cited by 41
Treatment of Primary Writing Tremor With Botulinum Toxin Type A Injections: Report of a Case Series
Papapetropoulos, S., & Singer, C. (2006) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000236765.00785.9c · Cited by 40
Current and Future Neuropharmacological Options for the Treatment of Essential Tremor
Alonso‐Navarro, H., García‐Martín, E., Agúndez, J. A. G., & Jiménez‐Jiménez, F. J. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200124145743 · Cited by 39
Hanajima, R., Ugawa, Y., Terao, Y., Sakai, K., Furubayashi, T., Machii, K., Uesugi, H., Mochizuki, H., & Kanazawa, I. (1998) · Electroencephalography and Clinical Neurophysiology/Electromyography and Motor Control · doi:10.1016/s0924-980x(98)00036-8 · Cited by 39
Effectiveness of BoNT A in Parkinson's Disease Upper Limb Tremor Management
Rahimi, F., Bee, C., Debicki, D., Roberts, A., Bapat, P., & Jog, M. (2013) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s031716710001489x · Cited by 37
An Update on the Use of Botulinum Toxin Therapy in Parkinson’s Disease
Mills, R., Bahroo, L. B., & Pagán, F. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0511-3 · Cited by 40
Evidence-Based Review of Patient-Reported Outcomes With Botulinum Toxin Type A
Jankovic, J. J., Esquenazi, A., Fehlings, D. L., Freitag, F. G., Lang, A. M., & Naumann, M. K. (2004) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000145508.84389.87 · Cited by 40
Self-citationPloumis, A., Varvarousis, D., Konitsiotis, S., & Beris, A. E. (2013) · Disability and Rehabilitation · doi:10.3109/09638288.2013.791727 · Cited by 36
“Some botulinum toxin users support that needle electromyography is not needed in the vast majority of patients (including forearm muscles) [20], except in rare instances when the muscles cannot be adequately palpated or when the patient does not obtain adequate relief.”
BackgroundBotulinum Toxin Type A Injections as Monotherapy for Upper Limb Essential Tremor Using Kinematics
Samotus, O., Kumar, N., Rizek, P., & Jog, M. (2017) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2017.260 · Cited by 34
“These studies used fixed dosages of BoNT-A into predetermined/randomized muscle groups, thus not an individualized approach, which failed to achieve significant functional improvements, despite at least a 50% reduction in tremor, due to lasting transient muscle weakness; hence, past studies were limited to one or two…”
BackgroundCaviness, J. N., & Kurth, M. (1997) · Movement Disorders · doi:10.1002/mds.870120633 · Cited by 34
Vagus nerve stimulation for essential tremor: A pilot efficacy and safety trial
Handforth, A., Ondo, W. G., Tatter, S. B., Mathern, G. W., Simpson, R. K., Walker, F. O., Sutton, J., Hubble, J. P., & Jankovic, J. J. (2003) · Neurology · doi:10.1212/01.wnl.0000094355.51119.d2 · Cited by 34
Self-citationKeren, O., Reznik, J., & Groswasser, Z. (2001) · Brain Injury · doi:10.1080/02699050010009568 · Cited by 32
Botulinum Toxin Treatment in Multiple Sclerosis—a Review
Safarpour, Y., Mousavi, T., & Jabbari, B. (2017) · Current Treatment Options in Neurology · doi:10.1007/s11940-017-0470-5 · Cited by 34
Comparison of three different kinematic sensor assemblies for locomotion study
Giansanti, D., & Maccioni, G. (2005) · Physiological Measurement · doi:10.1088/0967-3334/26/5/010 · Cited by 32
Jog, M., Lee, J., Scheschonka, A., Chen, R. E., Ismail, F., Boulias, C., Hobson, D. E., King, D., Althaus, M., Simon, O., et al. (2020) · Toxins · doi:10.3390/toxins12120807 · Cited by 31
“The second study randomized 25 patients to onabotulinumtoxinA 50 U or placebo into the same wrist muscles as the first study for 16 weeks [8].”
InfluentialAn Update on the Neurologic Applications of Botulinum Toxins
Evidente, V. G. H., & Adler, C. H. (2010) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-010-0129-z · Cited by 34
“A class II placebo-controlled study randomly assigned 25 patients with hand tremor to receive 50 U of Botox or placebo into the wrist flexors and flexors of the dominant upper limb [ 40 ].”
MethodRawicki, B., Sheean, G. L., Fung, V. S. C., Goldsmith, S. C., Morgan, C., & Novak, I. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03132.x · Cited by 31
“There is class II evidence that BoNT-A is effective in reducing the postural component of essential tremor of the upper limbs [52,53].”
BackgroundEpidemiology and Management of Essential Tremor in Children
Ferrara, J. M., & Jankovic, J. J. (2009) · Pediatric Drugs · doi:10.2165/11316050-000000000-00000 · Cited by 33
Self-citationMittal, S. O., Jog, M., Lee, J., & Jabbari, B. (2020) · Tremor and Other Hyperkinetic Movements · doi:10.5334/tohm.582 · Cited by 30
“In a double-blind, placebo-controlled study, Jankovic et al [13] administered onabotulinumtoxinA or saline to 25 individuals with ET.”
BackgroundInfluentialThe place of the botulinum toxin in the management of multiple sclerosis
Habek, M., Karni, A., Balash, Y., & Gurevich, T. (2010) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2010.04.010 · Cited by 29
“(32) There were similar results in another multicenter, double blind, controlled trial on 133 patients with”
Topiramate for essential tremor
Bruno, E., Nicoletti, A. S. Q., Quattrocchi, G., Allegra, R., Filippini, G., Colosimo, C., & Zappia, M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009683.pub2 · Cited by 30
Treatment of proximal upper limb tremor with botulinum toxin therapy
Kim, S. D., Yiannikas, C., Mahant, N., Vucic, S., & Fung, V. S. C. (2013) · Movement Disorders · doi:10.1002/mds.25739 · Cited by 28
Personalized Bilateral Upper Limb Essential Tremor Therapy with Botulinum Toxin Using Kinematics
Samotus, O., Lee, J., & Jog, M. (2019) · Toxins · doi:10.3390/toxins11020125 · Cited by 28
“Fixed-dose paradigms that are not titrated to the multi-joint and individual tremor severity cannot achieve these results [10,11].”
BackgroundRincón, F., & Louis, E. D. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.5.899 · Cited by 28
“It found no significant difference between the effects of botulinum toxin A at either dose in the severity of kinetic tremor, motor task performance, or functional disability [121,122].”
BackgroundLiao, Y.-H., Hong, C., & Huang, T. (2022) · Toxins · doi:10.3390/toxins14030203 · Cited by 27
“However, there was no significant improvement reported in the two studies [25,26] regarding anatomical guidance within 6 weeks (SMD = −0.”
BackgroundTherapeutic uses of botulinum toxin: from facial palsy to autonomic disorders
de Maio, M. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.6.791 · Cited by 26
“No significant improvement was found for kinetic hand tremor [57] .”
BackgroundPharmacotherapy with Botulinum Toxin: Harnessing Nature's Most Potent Neurotoxin
Bell, M. S., Vermeulen, L. C., & Sperling, K. B. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.13.1079.35040 · Cited by 26
Use of Botulinum Neurotoxin in Parkinson’s Disease: A Critical Appraisal
Jost, W. H. (2021) · Toxins · doi:10.3390/toxins13020087 · Cited by 26
Guidelines for the therapeutic use of botulinum toxin in movement disorders
Berardelli, A., Abbruzzese, G., Bertolasi, L., Cantarella, G., Carella, F., Currà, A., Grandis, D. D., Defazio, G., Galardi, G., Girlanda, P., et al. (1997) · The Italian Journal of Neurological Sciences · doi:10.1007/bf02083302 · Cited by 25
Botulinum toxin in movement disorders
Pandey, S., & Tater, P. (2018) · Neurology India · doi:10.4103/0028-3886.226441 · Cited by 24
Dexterity Training Improves Manual Precision in Patients Affected by Essential Tremor
Budini, F., Lowery, M. M., Hutchinson, M., Bradley, D., Conroy, L., & VITO, G. D. (2013) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2013.11.002 · Cited by 26
Temporal characteristics of botulinum neurotoxin therapy
Lebeda, F. J., Cer, R. Z., Stephens, R. M., & Mudunuri, U. S. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.134 · Cited by 24
Botulinum toxin in management of limb tremor
Zakin, E., & Simpson, D. (2017) · Toxins · doi:10.3390/toxins9110365 · Cited by 23
“used the clinical examination coupled with direct current amplification of EMG for the determination of accelerometry output for muscle selection in their randomized, double-blind, placebo-controlled study to evaluate toxin use in essential hand tremor [7].”
Method
Metadata
- Authors
- Jankovic, J., Schwartz, K., Clemence, W., Aswad, A., & Mordaunt, J.
- Affiliations
- Baylor College of Medicine (US)
- Corresponding author
- Jankovic, J.
- ORCID
- Jankovic, J.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 1996-05
- Volume
- 11
- Issue
- 3
- Pages
- 250-256
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2010076187
- Cited by
- 235
- References
- 15
- Citations by year
- 2026: 9 · 2025: 8 · 2024: 9 · 2023: 7 · 2022: 6 · 2021: 9 · 2020: 11 · 2019: 8 · 2018: 9 · 2017: 12 · 2016: 10 · 2015: 7 · 2014: 5 · 2013: 8 · 2012: 10
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Movement Disorders (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Keywords
- botulinum toxin type A, wrist flexors, wrist extensors, accelerometry, postural tremor, kinetic tremor, chemodenervation
- MeSH terms
- Aged, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Electromyography, Female, Hand, Humans, Injections, Intramuscular, Male, Middle Aged, Motor Skills, Neurologic Examination, Signal Processing, Computer-Assisted, Tremor, Treatment Outcome, Botulinum Toxins, Type A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.